Our Product Pipeline

Innovative pre-clinical development and extensive experience from clinical development of pharmaceuticals.

This is essential in order to take orphan and specialty pharmaceuticals to the market, and to deliver valuable products and product support to our patients and customers.

Related Information

Patients

Cerys living with hereditary tyrosinemia type 1 (HT-1)
Cerys living with hereditary tyrosinemia type 1 (HT-1)

Sobi develops, manufactures and sells medications for a number of diseases, with a special emphasis on four specialist areas: haemophilia, inflammation/autoimmune diseases, inherited metabolic diseases and oncology.

We focus on medications for rare disease patients with a high unmet medical need. This category includes specialist and so-called orphan drugs, which are mainly prescribed by clinical specialists and aimed at small well-defined patient groups. These less common diseases are often neglected and inadequately treated which means that new medications can offer significant value for the patient and health care providers.

Sobi provides specialty pharmaceuticals throughout Europe, Canada and the US. Our presence also includes distribution partnerships giving us reach in Asia, Australia, New Zealand and South America as well.

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne